Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Previously submitted to: JMIR Cancer (no longer under consideration since Sep 24, 2026)

Date Submitted: Sep 22, 2026
Open Peer Review Period: Sep 24, 2026 - Sep 24, 2026
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Incidence between JAKi exposure and subsequent malignancy in patients with partial immune diseases: A meta-analysis based on randomized controlled trial (RCTs) and long-term extended trial (LTEs)

  • Yuexiu Si

ABSTRACT

Background:

Janus kinase inhibitors (JAKi) represent an important therapeutic class of small-molecule targeted drugs that exert potent immunomodulatory and anti-inflammatory effects by inhibiting the Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling pathway.

Objective:

This study aimed to investigate the association between Janus kinase inhibitor (JAKi) exposure and the incidence of subsequent malignancy.

Methods:

We systematically searched five electronic databases from their inception to May 2025 to identify studies investigating the association between JAKi exposure and subsequent malignancy incidence. The primary outcome was the incidence of subsequent malignancy. Outcomes for dichotomous variables were assessed using risk ratios (RR) with 95% confidence intervals (CI), and prediction interval (PI). All statistical analyses employed random-effects models.

Results:

Sixty-eight randomized controlled trials (RCTs) and long-term extension studies (LTEs) were included, involving a total of more than 80,000 patients, the number of people with malignancies in the experimental group was 899, and the number of people with malignancies in the control group was 44. Overall, no significant association was observed between JAKi exposure and subsequent malignancy incidence in the overall pooled population (RR = 0.97 [0.71, 1.34]; PI = [0.38, 2.52]; P = 0.63; I²= 0%; τ²= 0.2). Within the study type subgroups (LTEs and RCTs), there were no significant differences in the incidence of malignant tumors between the experimental group and the control group. Subgroup analysis based on follow-up duration revealed no significant difference in subsequent malignancy incidence between groups, regardless of whether follow-up was ≤ 52 weeks or > 52 weeks. Similarly, no significant differences were found when stratifying by drug type. Analysis by subsequent malignancy type also showed no significant differences between general study population. Subgroup analysis of primary diseases showed no significant difference in malignancy rates in patients with inflammatory arthritis, gastrointestinal disease, and skin disease in the experimental and control groups after JAKi exposure.

Conclusions:

Existing data show that in specific patients, this JAKi did not observe significant differences in secondary malignancies; however, these findings still need further validation. The certainty of inference is limited by sparse events, short follow-up periods, population selection biases, and control heterogeneity.


 Citation

Please cite as:

Si Y

Incidence between JAKi exposure and subsequent malignancy in patients with partial immune diseases: A meta-analysis based on randomized controlled trial (RCTs) and long-term extended trial (LTEs)

JMIR Preprints. 22/09/2026:112695

DOI: 10.2196/preprints.112695

URL: https://preprints.jmir.org/preprint/112695

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.